Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test

YF Ghoos, BD Maes, BJ Geypens, G Mys, MI Hiele… - Gastroenterology, 1993 - Elsevier
Background: The aim of the present study was to develop a breath test for measuring gastric
emptying rate of solids that would induce less radiation exposure than radioscintigraphy …

[HTML][HTML] Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study

BD Maes, R Oyen, K Claes, P Evenepoel, D Kuypers… - Kidney international, 2004 - Elsevier
Maes is the holder of the Janssen-Cilag Chair for Nephrology at the University of Leuven.
The study medication was kindly provided by Hoffmann-LaRoche, Basel, Switzerland. The …

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

…, J Floege, G Hetzel, AG Jardine, F Locatelli, BD Maes… - The Lancet, 2017 - thelancet.com
Background IgA nephropathy is thought to be associated with mucosal immune system
dysfunction, which manifests as renal IgA deposition that leads to impairment and end-stage …

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

…, E Imai, TH Jafar, JB Lewis, PKT Li, BD Maes… - Nature medicine, 2023 - nature.com
Glomerular filtration rate (GFR) decline is causally associated with kidney failure and is a
candidate surrogate endpoint for clinical trials of chronic kidney disease (CKD) progression. …

Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors

BD Maes, D Kuypers, T Messiaen, P Evenepoel… - …, 2001 - journals.lww.com
Background. The development of posttransplantation diabetes mellitus has a major impact
on the quality of life and long-term outcome. Methods. One hundred thirty-nine patients …

Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis

…, JV Donadio, J Floege, PKT Li, BD Maes… - American Journal of …, 2021 - Elsevier
… Dr Maes holds the following positions: National Leader ASCEND ND and D trial, GSK;
National Leader Nefigard trial, Calliditas; National Leader, DUPLEX and PROTECT trial, Travere …

Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea

BD Maes, I Dalle, K Geboes, M Oellerich… - …, 2003 - journals.lww.com
Background. Diarrhea is the most frequently reported adverse event in mycophenolate mofetil
(MMF)-treated transplant patients. The aim of this study was to explore the gastrointestinal …

[HTML][HTML] Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus

…, H Holdaas, Y Vanrenterghem, BD Maes - American Journal of …, 2005 - Elsevier
Increased systemic exposure to statins and consequent risk for complications has been
reported in patients concomitantly treated with cyclosporin A (CsA). This has been ascribed to …

Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis

…, FP Schena, R Katafuchi, GB Appel, BD Maes… - American Journal of …, 2016 - Elsevier
… Dr Maes reports serving in a strategic advisory role to Pharmalink. Dr Praga reports receiving
fees for lectures and advisory boards for Alexion, Abbvie, Otsuka, Pharmalink, Astellas, …

Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation

…, JS Herrick, E Imai, TH Jafar, BD Maes… - Journal of the …, 2019 - journals.lww.com
Background Randomized trials of CKD treatments traditionally use clinical events late in CKD
progression as end points. This requires costly studies with large sample sizes and long …